Precemtabart tocentecan could soon become the industry's most advanced anti-CEACAM5 ADC.
ApexOnco Front Page
Recent articles
The company pays $2.5bn for Day One and its approved drug Ojemda.
After more discontinuations, a new deal brings in fresh blood.
Harmoni-A hits, backing a quiet disclosure about the Harmoni trial.
Inhibrx reveals three deaths in phase 1, but all predate screening protocols.
BG-75202 features among several projects starting first-in-human trials.
There will soon be three PD-(L)1 x VEGF projects in pivotal lung and colorectal cancer trials.
The Fortitude-102 trial, testing a bemarituzumab/Opdivo/chemo triplet, has failed.
